Finance

Lists
Why is 000105 up 6,74%?
Dive Deeper
000105:KRX
Yuhan Corp Preference Shares
71 300,00 KRW
+6,74%
(+4 500,00) 1D
19-окт., 15:30:30 GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 000105...
Open
66 800 KRW
High
71 700 KRW
Low
66 100 KRW
Mkt. cap
6,52 трлн
Avg. vol.
574,00
Volume
5,10 миң
Dividend
0,84%
Quarterly dividend
150 KRW
Ex-dividend date
2026-ж., 26-фев.
P/E ratio
22,41
52-wk high
115 300 KRW
52-wk low
55 100 KRW
EPS
3 181 KRW
Shares outstanding
1,15 млн
No. of employees
2 миң
Open
66 800 KRW
High
71 700 KRW
Low
66 100 KRW
Mkt. cap
6,52 трлн
Avg. vol.
574,00
Volume
5,10 миң
Dividend
0,84%
Quarterly dividend
150 KRW
Ex-dividend date
2026-ж., 26-фев.
P/E ratio
22,41
52-wk high
115 300 KRW
52-wk low
55 100 KRW
EPS
3 181 KRW
Shares outstanding
1,15 млн
No. of employees
2 миң
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
8 саат мурун
IBK cuts target for Yuhan stock to KRW 110,000
Profile
Yuhan Corporation is a South Korean pharmaceutical and chemical company headquartered in Daebang-dong, Dongjak-gu, Seoul. It was established in 1926 by New Il-han and has been listed on the Korea Stock Exchange since 1962. Yuhan is one of the top Korean pharmaceutical companies, along with Celltrion, Samsung Biologics, GC Pharma, and Hanmi Pharmaceutical. Wikipedia
About Yuhan Corp Preference Shares
CEOWook Je Cho
Employees2,08 миң
Founded1926
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
570,01 млд
546,07 млд
526,78 млд
639,45 млд
Cost of goods sold
401,57 млд
333,27 млд
377,63 млд
411,75 млд
Cost of revenue
401,57 млд
333,27 млд
377,63 млд
411,75 млд
Research and development expenses
45,94 млд
78,04 млд
47,24 млд
60,12 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
94,69 млд
103,16 млд
88,43 млд
99,40 млд
Operating expense
146,43 млд
185,79 млд
140,37 млд
160,70 млд
Total operating expenses
548,00 млд
519,05 млд
518,00 млд
572,45 млд
Operating income
22,01 млд
27,02 млд
8,78 млд
67,00 млд
Other non operating income
-2,09 млд
-4,58 млд
231,25 млн
-6,59 млд
EBT including unusual items
35,18 млд
120,91 млд
28,76 млд
88,37 млд
EBT excluding unusual items
34,24 млд
112,36 млд
26,45 млд
84,89 млд
Income tax expense
14,01 млд
10,77 млд
5,39 млд
20,33 млд
Effective tax rate
39,83%
8,91%
18,75%
23,00%
Other operating expenses
1,68 млд
3,00 млд
1,94 млд
2,87 млд
Net income
25,28 млд
114,43 млд
27,04 млд
70,32 млд
Net profit margin
4,44%
20,96%
5,13%
11,00%
Earnings per share
348,00
1,53 миң
372,00
950,00
Interest and investment income
2,11 млд
2,13 млд
2,35 млд
2,47 млд
Interest expense
-3,99 млд
-3,91 млд
-3,86 млд
-3,89 млд
Net interest expenses
-1,88 млд
-1,77 млд
-1,51 млд
-1,42 млд
Depreciation and amortization charges
2,12 млд
962,24 млн
1,52 млд
1,48 млд
EBITDA
40,00 млд
44,17 млд
27,88 млд
90,47 млд
Gain or loss from assets sale
9,44 млн
-9,65 млд
15,64 млн
291,06 млн
AI content may include mistakes. Learn more
Google колдонмолору